The 2026 SNO/ASCO CNS Metastases Conference will feature multiple Independent Supported Symposia (ISS) Sessions. Morning, lunchtime and evening sessions will be offered. Below is a list of the confirmed ISS sessions.

Thursday, August 13, 2026

6:15 PM - 7:15 PM

Redefining the Management of Leptomeningeal Metastases: Integrating Diagnostics, Molecular Insights, and Emerging Therapies

Location: Essex North/Center Ballroom 

Registration: Click here.

Speakers:

Jessica Wilcox, MD

Memorial Sloan Kettering Cancer Center

Micheal Youseff, MD

Houston Methodist

Rupesh Kotecha, MD

Baptist Health Herbert Wertheim Cancer Institute

Session Agenda:

• Leptomeningeal Metastases: Current Landscape, Unmet Needs, and Clinical Challenges
• Precision Diagnostics for LM: The Expanding Role of CSF-Based Biomarkers
• Emerging Therapeutic Strategies for LM: Latest Data and Future Directions
• The Future of LM Management: Harnessing Data Analytics, Artificial Intelligence, and Precision Medicine
• Panel Discussion: What Will Precision LM Care Look Like in 2030?

Supported by Cerenome Previously Plus Therapeutics.

Friday, August 14, 2026

7:15 AM - 8:15 AM

Use of 18-FET-PET in Brain Tumor Management: Clinical Cases and Patient Management Impact

Location: Essex North/Center Ballroom

Registration: Click here.

Speaker:

Michael Veronesi, MD

University of Wisconsin

Learning Objectives:

• Recognize the limitations of conventional imaging for primary and secondary brain tumors
• Understand the mechanism of action of the amino acid radiotracers for brain tumor imaging
• Review the accuracy of FET-PET in various clinical scenarios PET RANO and the recent NCCN Guidelines inclusion
• Learn from real-world case studies of the value of FET-PET in primary and secondary brain tumor imaging

Supported by Telix Pharmaceuticals.

12:50 PM - 1:50 PM

GammaTile Presents: Closing the Treatment Gap - How Immediate Radiation Improves Outcomes

Location: Essex North/Center Ballroom

Registration: Click here.

Speakers:

Lindsey Sloan, MD, PhD

University of Minnesota Brain Tumor Program

Simon Hanft, MD, FAANS

New York Medical College

Post-operative radiation is the standard of care, but it is not the standard outcome. This session explores the disconnect between guideline intent and

 real-world delivery, and presents Phase 3, multi-center evidence from the ROADS trial demonstrating superior outcomes, including significantly improved

overall survival and a lower rate of tumor regrowth, with immediate, guaranteed radiation.

Supported by GammaTile.

Advances in CSF-based liquid biopsy solutions for CNS malignancies

Location: Essex South Ballroom 

Speakers:

Omar H Butt, MD PhD

Washington University, St. Louis Missouri

Na Tosha N. Gatson, MD, PhD, FAAN

Indiana University Health

Part 1: Diagnosis and risk stratification of brain lesions is challenging when tissue biopsy is contraindicated due to anatomic or clinical factors.

Cerebrospinal fluid (CSF)–based liquid biopsy using cell-free DNA (cfDNA) and RNA (cfRNA) offers a minimally invasive approach to detect

neoplastic disease and inform management. We evaluated the clinical utility of a commercially available cfDNA/cfRNA next-generation sequencing

 assay applied to CSF specimens from patients with central nervous system (CNS) lesions of uncertain etiology.

Part 2: Enumeration and detection of HER biomarker status on circulating tumor cells (CTCs) in cerebrospinal fluid (CSF) has clinically actionable insights

that could expand therapeutic options for patients with leptomeningeal metastasis (LM). Done in combination for select patients, information derived from

cell free DNA/RNA (cfDNA/RNA) analysis could provide early indicators of developing tumor resistance to systemic therapies and inform therapeutic pivot

for improved patient outcomes.

Supported by Genomic Testing Cooperative + Menarini Biosystems

Saturday, August 15, 2026

7:15 AM - 8:15 AM

Clinical Utility of CSF Liquid Biopsy from Belay Diagnostics

Location: Essex North/Center Ballroom 

Speakers:

Michael Youssef, MD

Cameron L. Lilly, Ph.D

Supported by Belay Diagnostics.

12:40 PM - 1:40 PM

Local Chemotherapy Targeting Residual Disease at the Time of Resection

Location: Essex North/Center Ballroom 

Supported by Azurity.